#carcinoma — Monday, September 07, 2026 (1 items)
| 0 | ℹ |
Tislelizumab plus lenvatinib in advanced fumarate hydratase-deficient renal cell carcinoma: a single-arm, phase 2 trial with metabolic biomarker analysis.
(nature.com)
|
Nature Communications 2026-09-07 | #immunotherapy #oncology #biomarker #carcinoma #metabolism |